Humacyte announces common stock offering, no amount given

Humacyte announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by Humacyte. Humacyte intends to use the net proceeds that it will receive from the offering to continue the advancement of its pipeline in regenerative medicine, to support the FDA’s review of its Biologics License Application seeking approval of Humacyte’s bioengineered human acellular vessels in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein use is not feasible, to establish its initial commercial infrastructure in anticipation of future potential commercial launches and for general corporate purposes. TD Cowen and Cantor are acting as joint book-running managers for the offering. BTIG is acting as lead manager.